{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:06:33Z","timestamp":1793318793004,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001059","name":"Australian Pain Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001059","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.neuropharm.2021.108529","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:34:37Z","timestamp":1616027677000},"page":"108529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Oral efficacy of \u0394(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model"],"prefix":"10.1016","volume":"189","author":[{"given":"Vanessa A.","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9112-3369","authenticated-orcid":false,"given":"Juliette","family":"Harley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherelle L.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arabella C.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryony L.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4314-7689","authenticated-orcid":false,"given":"Christopher W.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108529_bib1","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41386-019-0585-3","article-title":"Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain","volume":"45","author":"Abraham","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108529_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2021.108529_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1744-8069-10-26","article-title":"A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments","volume":"10","author":"Bonin","year":"2014","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2021.108529_bib4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.drugalcdep.2017.01.046","article-title":"Cannabidiol-Delta9-tetrahydrocannabinol interactions on acute pain and locomotor activity","volume":"175","author":"Britch","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2021.108529_bib5","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1097\/j.pain.0000000000001051","article-title":"Cannabis constituent synergy in a mouse neuropathic pain model","volume":"158","author":"Casey","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2021.108529_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejps.2017.07.003","article-title":"The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model","volume":"109","author":"Cherniakov","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.neuropharm.2021.108529_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2006.11.006","article-title":"The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain","volume":"556","author":"Costa","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108529_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.transproceed.2017.12.042","article-title":"Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay","volume":"50","author":"Cu\u00f1etti","year":"2018","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.neuropharm.2021.108529_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2004.03.051","article-title":"Pharmacological characterization of the chronic constriction injury model of neuropathic pain","volume":"491","author":"De Vry","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108529_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biopsych.2014.04.009","article-title":"Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal","volume":"77","author":"Deng","year":"2015","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108529_bib11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","article-title":"Recommendations for the pharmacological management of neuropathic pain: an overview and literature update","volume":"85","author":"Dworkin","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.neuropharm.2021.108529_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2021.108529_bib13","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(19)31789-1","article-title":"Public health implications of legalising the production and sale of cannabis for medicinal and recreational use","volume":"394","author":"Hall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2021.108529_bib14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1055\/s-0042-106303","article-title":"Effects of delta-9-tetrahydrocannabinol and cannabidiol on cisplatin-induced neuropathy in mice","volume":"82","author":"Harris","year":"2016","journal-title":"Planta Med."},{"key":"10.1016\/j.neuropharm.2021.108529_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.brainres.2007.09.090","article-title":"Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism","volume":"1188","author":"Hayakawa","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108529_bib16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.euroneuro.2017.10.037","article-title":"Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC","volume":"27","author":"Hlo\u017eek","year":"2017","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2021.108529_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/3-540-26573-2_23","article-title":"Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol","author":"Huestis","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108529_bib18","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.pain.2011.06.017","article-title":"A new definition of neuropathic pain","volume":"152","author":"Jensen","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2021.108529_bib19","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1111\/bph.13887","article-title":"Single and combined effects of \u0394(9) -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain","volume":"174","author":"King","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108529_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-011-2342-0","article-title":"Cannabidiol potentiates Delta(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats","volume":"218","author":"Klein","year":"2011","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108529_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.177.4043.62","article-title":"11-hydroxy- 9 -tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man","volume":"177","author":"Lemberger","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2021.108529_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234176","article-title":"Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of \u03949-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination","volume":"15","author":"Linher-Melville","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2021.108529_bib23","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108529_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","article-title":"Practical considerations in medical cannabis administration and dosing","volume":"49","author":"MacCallum","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.neuropharm.2021.108529_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrn3811","article-title":"Early phytocannabinoid chemistry to endocannabinoids and beyond","volume":"15","author":"Mechoulam","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108529_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/can.2015.0004","article-title":"Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid","volume":"1","author":"Merrick","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.neuropharm.2021.108529_bib27","first-page":"79","article-title":"Short-term efficacy of CBD-enriched hemp oil in girls with dysautonomic syndrome after human papillomavirus vaccination","volume":"19","author":"Palmieri","year":"2017","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.neuropharm.2021.108529_bib28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","article-title":"Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside","volume":"6","author":"Rahn","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2021.108529_bib29","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","article-title":"Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies","volume":"159","author":"Stockings","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2021.108529_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104117","article-title":"An overview of drug combination analysis with isobolograms","volume":"319","author":"Tallarida","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108529_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1124\/jpet.103.054320","article-title":"Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice","volume":"307","author":"Tallarida","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108529_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1744-8069-6-16","article-title":"Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain","volume":"6","author":"Toth","year":"2010","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2021.108529_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40122-019-0114-4","article-title":"An update of current cannabis-based pharmaceuticals in pain medicine","volume":"8","author":"Urits","year":"2019","journal-title":"Pain Ther"},{"key":"10.1016\/j.neuropharm.2021.108529_bib34","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.mayocp.2019.01.003","article-title":"Clinicians' guide to cannabidiol and hemp oils","volume":"94","author":"VanDolah","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.neuropharm.2021.108529_bib35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00213-006-0356-9","article-title":"Interactions between THC and cannabidiol in mouse models of cannabinoid activity","volume":"186","author":"Varvel","year":"2006","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108529_bib36","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1111\/bph.14958","article-title":"Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: opposite roles of CB(1)\/CB(2) versus GPR55 receptors","volume":"177","author":"Wang","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108529_bib37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bph.12439","article-title":"Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy","volume":"171","author":"Ward","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108529_bib38","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2021.108529_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejphar.2007.12.035","article-title":"Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception","volume":"584","author":"Williams","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108529_bib40","doi-asserted-by":"crossref","first-page":"103202","DOI":"10.1016\/j.etap.2019.103202","article-title":"Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model","volume":"70","author":"Xu","year":"2019","journal-title":"Environ. Toxicol. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:07:37Z","timestamp":1758438457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":40,"alternative-id":["S0028390821000836"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108529","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral efficacy of \u0394(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108529"}}